Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032

PURPOSE: Two phase II studies assessed the efficacy of vismodegib, a sonic hedgehog (SHH) pathway inhibitor that binds smoothened (SMO), in pediatric and adult recurrent medulloblastoma (MB). PATIENTS AND METHODS: Adult patients enrolled onto PBTC-025B and pediatric patients enrolled onto PBTC-032 w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Robinson, Giles W., Orr, Brent A., Wu, Gang, Gururangan, Sridharan, Lin, Tong, Qaddoumi, Ibrahim, Packer, Roger J., Goldman, Stewart, Prados, Michael D., Desjardins, Annick, Chintagumpala, Murali, Takebe, Naoko, Kaste, Sue C., Rusch, Michael, Allen, Sariah J., Onar-Thomas, Arzu, Stewart, Clinton F., Fouladi, Maryam, Boyett, James M., Gilbertson, Richard J., Curran, Tom, Ellison, David W., Gajjar, Amar
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4534527/
https://ncbi.nlm.nih.gov/pubmed/26169613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.1591
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados